{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:01:45Z","timestamp":1789682505822,"version":"4.0.1"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.resinv.2024.12.017","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T07:38:52Z","timestamp":1736926732000},"page":"200-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current drug therapy for pleural mesothelioma"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-4255","authenticated-orcid":false,"given":"Hisao","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.12.017_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant mesothelioma Mortality - United States, 1999-2015","volume":"66","author":"Mazurek","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.resinv.2024.12.017_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164194","article-title":"Epidemiology and clinical aspects of malignant pleural mesothelioma","volume":"13","author":"Brims","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.resinv.2024.12.017_bib3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib5","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.21037\/tlcr.2020.02.01","article-title":"How asbestos and other fibers cause mesothelioma","volume":"9","author":"Gaudino","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.resinv.2024.12.017_bib6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1379::AID-CNCR24>3.0.CO;2-Y","article-title":"Post-irradiation malignant mesothelioma","volume":"77","author":"Cavazza","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/thorax.58.9.809","article-title":"Lung cancer \u2217 8: management of malignant mesothelioma","volume":"58","author":"Parker","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2024.12.017_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2559.1997.5460776.x","article-title":"Pathology of malignant mesothelioma","volume":"30","author":"Attanoos","year":"1997","journal-title":"Histopathology"},{"key":"10.1016\/j.resinv.2024.12.017_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/his.15065","article-title":"Updates on grading mesothelioma","volume":"84","author":"Schulte","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.resinv.2024.12.017_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database","volume":"196","author":"Meyerhoff","year":"2015","journal-title":"J Surg Res"},{"key":"10.1016\/j.resinv.2024.12.017_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2024.12.017_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2022.03.012","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743","volume":"167","author":"Scherpereel","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib14","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1164\/ajrccm.157.5.9707141","article-title":"Mechanisms in the pathogenesis of asbestosis and silicosis","volume":"157","author":"Mossman","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.resinv.2024.12.017_bib16","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular Characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.resinv.2024.12.017_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.resinv.2024.12.017_bib18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, Genome-wide Copy number Aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2024.12.017_bib21","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a Series of 214 cases from the Bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib23","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lungcan.2020.02.006","article-title":"Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement","volume":"142","author":"Bronte","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2020.05.019","article-title":"NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer","volume":"146","author":"Leal","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153772","article-title":"Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected","volume":"231","author":"Cordier","year":"2022","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.resinv.2024.12.017_bib27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.cllc.2020.06.025","article-title":"Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901","volume":"21","author":"Dudek","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial","volume":"9","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib32","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib34","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1756-0500-5-482","article-title":"Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience","volume":"5","author":"Bearz","year":"2012","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.resinv.2024.12.017_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib36","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for research and treatment of cancer lung cancer Cooperative group","volume":"85","author":"van Meerbeeck","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib37","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.resinv.2024.12.017_bib39","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2024.12.017_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ajco.13455","article-title":"Bevacizumab plus cisplatin\/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: a Japanese safety study","volume":"17","author":"Nakano","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib41","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib43","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.21037\/jtd.2017.10.131","article-title":"Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma","volume":"10","author":"Zucali","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2024.12.017_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib45","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib47","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(20)30515-4","article-title":"Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study","volume":"9","author":"Yap","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib49","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib50","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2024.12.017_bib51","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib52","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib53","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103639","article-title":"A systematic review and meta-analysis of trials assessing PD-1\/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma","volume":"172","author":"Tagliamento","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.resinv.2024.12.017_bib55","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib56","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003288","article-title":"JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma","volume":"9","author":"Miyamoto","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057663","article-title":"Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial","volume":"12","author":"Kok","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.resinv.2024.12.017_bib59","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jtho.2023.02.003","article-title":"Brief Report: Canadian cancer trials group IND.227: a phase 2 randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171)","volume":"18","author":"Piccirillo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib60","series-title":"Foundation EIP","article-title":"A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma","author":"Foundation","year":"2024"},{"key":"10.1016\/j.resinv.2024.12.017_bib61","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2024.12.017_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310415","article-title":"Improvements in systemic therapies for advanced malignant mesothelioma","volume":"24","author":"Deiana","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2024.12.017_bib63","series-title":"BEAT-meso: a randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)\u2014results from the ETOP 13-18 trial","author":"Popat","year":"2024"},{"key":"10.1016\/j.resinv.2024.12.017_bib64","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtcvs.2018.10.039","article-title":"Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection","volume":"157","author":"Verma","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.resinv.2024.12.017_bib65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10147-015-0925-1","volume":"21","author":"Hasegawa","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib66","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib67","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1183\/09031936.00039510","article-title":"Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial","volume":"36","author":"Van Schil","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.12.017_bib68","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","article-title":"Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Weder","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","article-title":"Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients","volume":"117","author":"Sugarbaker","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.resinv.2024.12.017_bib70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2009.08.019","article-title":"Survival after trimodality therapy for malignant pleural mesothelioma: radical Pleurectomy, chemotherapy with Cisplatin\/Pemetrexed and radiotherapy","volume":"71","author":"Bolukbas","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib71","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2007.02.004","article-title":"Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results","volume":"57","author":"Rea","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib72","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jtcvs.2021.07.017","article-title":"Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma","volume":"163","author":"Hasegawa","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.resinv.2024.12.017_bib73","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01243894-200605000-00004","article-title":"Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial","volume":"1","author":"Flores","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib74","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant pleural mesothelioma: State-of-the-Art on current therapies and promises for the future","volume":"9","author":"Nicolini","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib75","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New Era for malignant pleural mesothelioma: Updates on therapeutic options","volume":"40","author":"Tsao","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib76","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib77","doi-asserted-by":"crossref","first-page":"89722","DOI":"10.18632\/oncotarget.21113","article-title":"Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients","volume":"8","author":"Marcq","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.resinv.2024.12.017_bib78","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12890-021-01513-7","article-title":"Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma","volume":"21","author":"Gray","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020282","article-title":"The Search for an interesting Partner to combine with PD-L1 blockade in mesothelioma: focus on TIM-3 and LAG-3","volume":"13","author":"Marcq","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.resinv.2024.12.017_bib80","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3004","article-title":"A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms","volume":"38","author":"Luke","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib81","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","article-title":"VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy","volume":"2","author":"Lines","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.resinv.2024.12.017_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib83","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.resinv.2024.12.017_bib84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40364-021-00264-1","article-title":"Anti-Mesothelin CAR T cell therapy for malignant mesothelioma","volume":"9","author":"Castelletti","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.resinv.2024.12.017_bib85","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.resinv.2024.12.017_bib86","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2024.12.017_bib87","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1186\/s12885-022-09686-y","article-title":"YAP1 is essential for malignant mesothelioma tumor maintenance","volume":"22","author":"Calvet","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.resinv.2024.12.017_bib88","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-LB319","article-title":"Abstract LB319: IAG933, a selective and orally efficacious YAP1\/WWTR1 (TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations","volume":"83","author":"Schmelzle","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.resinv.2024.12.017_bib89","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1470-2045(23)00446-1","article-title":"Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study","volume":"24","author":"Douma","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib90","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib91","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jtho.2021.10.022","article-title":"Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors","volume":"17","author":"Kosari","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.12.017_bib92","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.resinv.2024.12.017_bib93","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.12.017_bib94","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MCP.0000000000000578","article-title":"Advances in pathological diagnosis of mesothelioma: what pulmonologists should know","volume":"25","author":"Louw","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.resinv.2024.12.017_bib95","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T22:07:48Z","timestamp":1739916468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2212534525000012"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.12.017","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current drug therapy for pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}